166 related articles for article (PubMed ID: 12559512)
21. Clinical follow-up of 304 patients with multiple sclerosis three years after mitoxantrone treatment.
Debouverie M; Taillandier L; Pittion-Vouyovitch S; Louis S; Vespignani H
Mult Scler; 2007 Jun; 13(5):626-31. PubMed ID: 17548442
[TBL] [Abstract][Full Text] [Related]
22. [Evaluation of the long term effect of mitoxantrone on neurological disability in patients with active multiple sclerosis].
Mesaros S; Stojsavljević N; Dujmović I; Mandić E; Drulović J
Srp Arh Celok Lek; 2004; 132(7-8):209-13. PubMed ID: 15615176
[TBL] [Abstract][Full Text] [Related]
23. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of mitoxantrone use in primary and secondary progressive multiple sclerosis - study site experience based on the therapy of 104 patients.
Lasek-Bal A; Bartoszek K; Steposz A; Puz P; Bal W; Kazibutowska Z
Int J Neurosci; 2017 Oct; 127(10):859-863. PubMed ID: 27919195
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of mitoxantrone in pediatric patients with aggressive multiple sclerosis.
Etemadifar M; Afzali P; Abtahi SH; Ramagopalan SV; Nourian SM; Murray RT; Fereidan-Esfahani M
Eur J Paediatr Neurol; 2014 Mar; 18(2):119-25. PubMed ID: 24139067
[TBL] [Abstract][Full Text] [Related]
26. Mitoxantrone for multiple sclerosis.
Martinelli Boneschi F; Rovaris M; Capra R; Comi G
Cochrane Database Syst Rev; 2005 Oct; (4):CD002127. PubMed ID: 16235298
[TBL] [Abstract][Full Text] [Related]
27. Mitoxantrone as rescue therapy in worsening relapsing-remitting MS patients receiving IFN-beta.
Correale J; Rush C; Amengual A; Goicochea MT
J Neuroimmunol; 2005 May; 162(1-2):173-83. PubMed ID: 15833373
[TBL] [Abstract][Full Text] [Related]
28. [Mitoxantrone (Novantron) in therapy of severe multiple sclerosis. A retrospective study of 15 patients].
Cursiefen S; Flachenecker P; Rieckmann P; Toyka KV
Nervenarzt; 1999 Aug; 70(8):723-31. PubMed ID: 10483572
[TBL] [Abstract][Full Text] [Related]
29. [Newer disease--modifying drugs: glatiramer acetate and mitoxantrone].
Kohriyama T; Higaki M; Matsumoto M
Nihon Rinsho; 2003 Aug; 61(8):1381-7. PubMed ID: 12962027
[TBL] [Abstract][Full Text] [Related]
30. Review of mitoxantrone in the treatment of multiple sclerosis.
Jeffery DR; Herndon R
Neurology; 2004 Dec; 63(12 Suppl 6):S19-24. PubMed ID: 15623665
[TBL] [Abstract][Full Text] [Related]
31. FDA backs cancer drug for treating MS.
Case Manager; 2000; 11(2):22. PubMed ID: 11935515
[No Abstract] [Full Text] [Related]
32. Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis.
Esposito F; Radaelli M; Martinelli V; Sormani MP; Martinelli Boneschi F; Moiola L; Rocca MA; Rodegher M; Comi G
Mult Scler; 2010 Dec; 16(12):1490-9. PubMed ID: 20810516
[TBL] [Abstract][Full Text] [Related]
33. Intravenous immunoglobulin and mitoxantrone stop the progression of secondary progressive multiple sclerosis in a patient with interferon intolerance.
Rodríguez Orozco AR
Rev Alerg Mex; 2004; 51(3):124-6. PubMed ID: 15314844
[TBL] [Abstract][Full Text] [Related]
34. Mitoxantrone in worsening secondary progressive multiple sclerosis: A prospective, open-label study.
Khatri BO; Wroblewski M; Kramer J; Dukic M; Poplar A; Anderson AJ
Curr Ther Res Clin Exp; 2006 Jan; 67(1):55-65. PubMed ID: 24678083
[TBL] [Abstract][Full Text] [Related]
35. [Mitoxantrone for the treatment of Japanese patients with multiple sclerosis].
Komori M; Tanaka M; Muramoto E; Ohno M; Matsumoto R; Murase N; Kitagawa N; Saida T
Rinsho Shinkeigaku; 2007 Jul; 47(7):401-6. PubMed ID: 17710882
[TBL] [Abstract][Full Text] [Related]
36. Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study.
Le Page E; Leray E; Edan G;
Mult Scler; 2011 Jul; 17(7):867-75. PubMed ID: 21325016
[TBL] [Abstract][Full Text] [Related]
37. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study.
Lublin FD; Bowen JD; Huddlestone J; Kremenchutzky M; Carpenter A; Corboy JR; Freedman MS; Krupp L; Paulo C; Hariri RJ; Fischkoff SA
Mult Scler Relat Disord; 2014 Nov; 3(6):696-704. PubMed ID: 25891548
[TBL] [Abstract][Full Text] [Related]
38. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
Sørensen PS
J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763
[TBL] [Abstract][Full Text] [Related]
39. Escalating immunotherapy with mitoxantrone in patients with very active relapsing-remitting or progressive multiple sclerosis.
Cursiefen S; Flachenecker P; Toyka KV; Rieckmann P
Eur Neurol; 2000; 43(3):186-7. PubMed ID: 10765063
[No Abstract] [Full Text] [Related]
40. Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial.
Edan G; Comi G; Le Page E; Leray E; Rocca MA; Filippi M;
J Neurol Neurosurg Psychiatry; 2011 Dec; 82(12):1344-50. PubMed ID: 21436229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
